167 related articles for article (PubMed ID: 15623654)
41. Reversal effects of pantoprazole on multidrug resistance in human gastric adenocarcinoma cells by down-regulating the V-ATPases/mTOR/HIF-1α/P-gp and MRP1 signaling pathway in vitro and in vivo.
Chen M; Huang SL; Zhang XQ; Zhang B; Zhu H; Yang VW; Zou XP
J Cell Biochem; 2012 Jul; 113(7):2474-87. PubMed ID: 22396185
[TBL] [Abstract][Full Text] [Related]
42. Pantoprazole-induced recurrent anaphylactic shock.
Fardet L; Izzedine H; Ciroldi M; Tiev KP; Cabane J
Am J Gastroenterol; 2002 Nov; 97(11):2933. PubMed ID: 12425583
[No Abstract] [Full Text] [Related]
43. Continuing development of acid pump inhibitors: site of action of pantoprazole.
Shin JM; Besancon M; Prinz C; Simon A; Sachs G
Aliment Pharmacol Ther; 1994; 8 Suppl 1():11-23. PubMed ID: 7514042
[TBL] [Abstract][Full Text] [Related]
44. Effect of proton pump inhibitors on hepatic regeneration.
Kucuk HF; Akyol H; Kaptanoglu L; Kurt N; Barisik NO; Bingul S; Torlak OA; Colak E
Eur Surg Res; 2006; 38(3):322-8. PubMed ID: 16785731
[TBL] [Abstract][Full Text] [Related]
45. By 1023/SK&F 96022: biochemistry of a novel (H+ + K+)-ATPase inhibitor.
Simon WA; Keeling DJ; Laing SM; Fallowfield C; Taylor AG
Biochem Pharmacol; 1990 Jun; 39(11):1799-806. PubMed ID: 2160820
[TBL] [Abstract][Full Text] [Related]
46. Effects of pantoprazole in experimental acute pancreatitis.
Hackert T; Tudor S; Felix K; Dovshanskiy D; Hartwig W; Simon WA; Werner J
Life Sci; 2010 Oct; 87(17-18):551-7. PubMed ID: 20851132
[TBL] [Abstract][Full Text] [Related]
47. Direct comparison between the ulcer-healing effects of two H(+)-K(+)-ATPase inhibitors, one M1-selective antimuscarinic and one H2 receptor antagonist in the rat.
Kromer W; Gönne S; Riedel R; Postius S
Pharmacology; 1990; 41(6):333-7. PubMed ID: 1982899
[TBL] [Abstract][Full Text] [Related]
48. Pantoprazole: a novel H+/K(+)-ATPase inhibitor with an improved pH stability.
Beil W; Staar U; Sewing KF
Eur J Pharmacol; 1992 Aug; 218(2-3):265-71. PubMed ID: 1330598
[TBL] [Abstract][Full Text] [Related]
49. Antral G cells in rats during dosing with a PPAR alpha agonist: a morphometric and immunocytochemical study.
Martinsen TC; Skogaker NE; Bendheim MØ; Waldum HL
Med Electron Microsc; 2003 Mar; 36(1):18-32. PubMed ID: 12658348
[TBL] [Abstract][Full Text] [Related]
50. [In small steps to far ahead. Diminished risk of interactions as definite advantage].
MMW Fortschr Med; 2002 Oct; 144(41):48-9. PubMed ID: 12474363
[No Abstract] [Full Text] [Related]
51. Proton pump inhibitor pantoprazole inhibits the proliferation, self‑renewal and chemoresistance of gastric cancer stem cells via the EMT/β‑catenin pathways.
Feng S; Zheng Z; Feng L; Yang L; Chen Z; Lin Y; Gao Y; Chen Y
Oncol Rep; 2016 Dec; 36(6):3207-3214. PubMed ID: 27748935
[TBL] [Abstract][Full Text] [Related]
52. Immunopotentiating effect of proton pump inhibitor pantoprazole in a lymphoma-bearing murine host: Implication in antitumor activation of tumor-associated macrophages.
Vishvakarma NK; Singh SM
Immunol Lett; 2010 Nov; 134(1):83-92. PubMed ID: 20837061
[TBL] [Abstract][Full Text] [Related]
53. Update on prescribing information for pantoprazole.
Karlstadt RG; Walker K
Am Fam Physician; 2003 Mar; 67(6):1189-90; author reply 1190. PubMed ID: 12674447
[No Abstract] [Full Text] [Related]
54. (H+,K+)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles. 4. A novel series of dimethoxypyridyl-substituted inhibitors with enhanced selectivity. The selection of pantoprazole as a clinical candidate.
Kohl B; Sturm E; Senn-Bilfinger J; Simon WA; Krüger U; Schaefer H; Rainer G; Figala V; Klemm K
J Med Chem; 1992 Mar; 35(6):1049-57. PubMed ID: 1313110
[TBL] [Abstract][Full Text] [Related]
55. Mechanisms of tumor growth retardation by modulation of pH regulation in the tumor-microenvironment of a murine T cell lymphoma.
Vishvakarma NK; Singh SM
Biomed Pharmacother; 2011 Feb; 65(1):27-39. PubMed ID: 20685069
[TBL] [Abstract][Full Text] [Related]
56. The proton pump inhibitor, E3810, binds to the N-terminal half of the alpha-subunit of gastric H+,K(+)-ATPase.
Morii M; Hamatani K; Takeguchi N
Biochem Pharmacol; 1995 Jun; 49(12):1729-34. PubMed ID: 7598734
[TBL] [Abstract][Full Text] [Related]
57. The DNA methyltransferase inhibitor zebularine induces mitochondria-mediated apoptosis in gastric cancer cells in vitro and in vivo.
Tan W; Zhou W; Yu HG; Luo HS; Shen L
Biochem Biophys Res Commun; 2013 Jan; 430(1):250-5. PubMed ID: 23167995
[TBL] [Abstract][Full Text] [Related]
58. The site of action of pantoprazole in the gastric H+/K(+)-ATPase.
Shin JM; Besancon M; Simon A; Sachs G
Biochim Biophys Acta; 1993 Jun; 1148(2):223-33. PubMed ID: 8389196
[TBL] [Abstract][Full Text] [Related]
59. Different biochemical modes of action of two irreversible H+,K(+)-ATPase inhibitors, omeprazole and E3810.
Morii M; Takeguchi N
J Biol Chem; 1993 Oct; 268(29):21553-9. PubMed ID: 8408006
[TBL] [Abstract][Full Text] [Related]
60. Preparation, characterization, and in vivo anti-ulcer evaluation of pantoprazole-loaded microparticles.
Raffin RP; Colomé LM; Pohlmann AR; Guterres SS
Eur J Pharm Biopharm; 2006 Jun; 63(2):198-204. PubMed ID: 16531029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
